Free tool
FAERS Monitor: Zyrtec-D 12 Hour
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 021150 or its brand name (Zyrtec-D 12 Hour, Cetirizine Hydrochloride, Pseudoephedrine Hydrochloride). Reports on generic versions are filed under their own applications.
Reports
3,003
Serious
1,129
38% of reports
Hospitalization
516
Death reported
320
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective563
- fatigue414
- pain407
- off label use389
- rash361
- abdominal discomfort339
- alopecia335
- rheumatoid arthritis331
- pemphigus330
- systemic lupus erythematosus320
- product use issue306
- maternal exposure during pregnancy304
- glossodynia299
- hand deformity294
- swelling294
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2005 | 1 |
| 2006 | 13 |
| 2007 | 35 |
| 2008 | 4 |
| 2010 | 3 |
| 2011 | 4 |
| 2012 | 27 |
| 2013 | 55 |
| 2014 | 48 |
| 2015 | 293 |
| 2016 | 348 |
| 2017 | 289 |
| 2018 | 140 |
| 2019 | 157 |
| 2020 | 189 |
| 2021 | 175 |
| 2022 | 227 |
| 2023 | 271 |
| 2024 | 258 |
| 2025 | 300 |
| 2026 | 165 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,051,156 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| pemphigusSignal | 330 | 189.9 | 171.2 | 60,214 |
| hand deformitySignal | 294 | 160.6 | 143.8 | 45,447 |
| glossodyniaSignal | 299 | 94.8 | 85.1 | 27,318 |
| systemic lupus erythematosusSignal | 320 | 63.7 | 57.4 | 19,546 |
| maternal exposure during pregnancySignal | 304 | 24.0 | 21.5 | 6,674 |
| swellingSignal | 294 | 22.1 | 19.8 | 5,900 |
| rheumatoid arthritisSignal | 331 | 20.5 | 18.5 | 6,128 |
| abdominal discomfortSignal | 339 | 14.2 | 12.8 | 4,165 |
| alopeciaSignal | 335 | 12.0 | 10.8 | 3,382 |
| product use issueSignal | 306 | 11.4 | 10.3 | 2,921 |
| rashSignal | 361 | 5.8 | 5.3 | 1,460 |
| painSignal | 407 | 4.6 | 4.2 | 1,194 |
| fatigueSignal | 414 | 3.7 | 3.4 | 854 |
| off label useSignal | 389 | 3.1 | 2.8 | 579 |
| drug ineffectiveSignal | 563 | 3.0 | 2.8 | 795 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.